uniQure N.V. Deferred Foreign Income Tax Expense (Benefit)
uniQure N.V. (QURE) reported Deferred Foreign Income Tax Expense (Benefit) of $1.12 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-03-02
- uniQure N.V. deferred foreign income tax expense (benefit) for the quarter ending 2025-12-31 was $3.00K, a 99.66% decline year-over-year.
- uniQure N.V. deferred foreign income tax expense (benefit) for the quarter ending 2025-09-30 was $245.00K.
- uniQure N.V. deferred foreign income tax expense (benefit) for the quarter ending 2024-12-31 was $871.00K.
- uniQure N.V. deferred foreign income tax expense (benefit) for the quarter ending 2024-09-30 was -$120.00K.
- uniQure N.V. deferred foreign income tax expense (benefit) for fiscal 2025 was $1.12M, a 50.88% decline from fiscal 2024.
- uniQure N.V. deferred foreign income tax expense (benefit) for fiscal 2024 was $2.28M, a 26.12% increase from fiscal 2023.
- uniQure N.V. deferred foreign income tax expense (benefit) for fiscal 2023 was $1.81M.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 3 month | Deferred Foreign Income Tax Expense (Benefit) 6 month | Deferred Foreign Income Tax Expense (Benefit) 9 month | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $248.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.12M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $245.00K 10-Q · filed 2025-11-10 | $1.12M 10-Q · filed 2025-11-10 | ||
| 2024-12-31 | $871.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $751.00K derived: sum of 2 quarters · filed 2026-03-02 | $2.28M 10-K · filed 2026-03-02 | |
| 2024-09-30 | -$120.00K 10-Q · filed 2025-11-10 | $1.41M 10-Q · filed 2025-11-10 | ||
| 2023-12-31 | $1.81M 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |